{"id":5658,"date":"2006-07-06T08:52:00","date_gmt":"2006-07-06T08:52:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=5658"},"modified":"2021-07-09T11:13:32","modified_gmt":"2021-07-09T11:13:32","slug":"treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study\/","title":{"rendered":"Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Giampaolo+B&amp;cauthor_id=16610021\">Bresci Giampaolo<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16610021\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Giuseppe+P&amp;cauthor_id=16610021\">Parisi Giuseppe<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Michele+B&amp;cauthor_id=16610021\">Bertoni Michele<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Alessandro+M&amp;cauthor_id=16610021\">Mazzoni Alessandro<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Fabrizio+S&amp;cauthor_id=16610021\">Scatena Fabrizio<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Alfonso+C&amp;cauthor_id=16610021\">Capria Alfonso<\/a>, World J Gastroenterol. 2006 Apr 14;12(14):2201-4.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Even if the number of our patients with steroid-refractory IBDs was not big, we can assert that GCAP is well tolerated and effective, especially in the first six months after the treatment, in a significant percentage of cases. The rate of sustained response drops slightly after 6 mo and significantly after 12 mo, however the absence of severe side effects can be a stimulus for further evaluating new schedules of treatment.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16610021\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/16610021\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Bresci Giampaolo&nbsp;1,&nbsp;Parisi Giuseppe,&nbsp;Bertoni Michele,&nbsp;Mazzoni Alessandro,&nbsp;Scatena Fabrizio,&nbsp;Capria Alfonso, World J Gastroenterol. 2006 Apr 14;12(14):2201-4. Even if the number of our patients with steroid-refractory IBDs was not big, we can assert that GCAP is well tolerated and effective, especially in the first six months after the treatment, in a significant percentage of cases. The rate of sustained [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[330,159,314,97,135,306],"class_list":["post-5658","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-clinical-trial","scientific_tags-crohns-disease","scientific_tags-digestive","scientific_tags-prospective","scientific_tags-steroid-refractory","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Bresci Giampaolo&nbsp;1,&nbsp;Parisi Giuseppe,&nbsp;Bertoni Michele,&nbsp;Mazzoni Alessandro,&nbsp;Scatena Fabrizio,&nbsp;Capria Alfonso, World J Gastroenterol. 2006 Apr 14;12(14):2201-4. Even if the number of our patients with steroid-refractory IBDs was not big, we can assert that GCAP is well tolerated and effective, especially in the first six months after the treatment, in a significant percentage of cases. The rate of sustained [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-09T11:13:32+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study\/\",\"name\":\"Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2006-07-06T08:52:00+00:00\",\"dateModified\":\"2021-07-09T11:13:32+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study\/","og_locale":"es_ES","og_type":"article","og_title":"Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study - Adacyte","og_description":"Bresci Giampaolo&nbsp;1,&nbsp;Parisi Giuseppe,&nbsp;Bertoni Michele,&nbsp;Mazzoni Alessandro,&nbsp;Scatena Fabrizio,&nbsp;Capria Alfonso, World J Gastroenterol. 2006 Apr 14;12(14):2201-4. Even if the number of our patients with steroid-refractory IBDs was not big, we can assert that GCAP is well tolerated and effective, especially in the first six months after the treatment, in a significant percentage of cases. The rate of sustained [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study\/","og_site_name":"Adacyte","article_modified_time":"2021-07-09T11:13:32+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study\/","name":"Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2006-07-06T08:52:00+00:00","dateModified":"2021-07-09T11:13:32+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/treatment-of-active-steroid-refractory-inflammatory-bowel-diseases-with-granulocytapheresis-our-experience-with-a-prospective-study\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/5658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=5658"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=5658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}